Selected article for: "antiviral activity and cytokine production"

Author: Rhein, Bethany A.; Powers, Linda S.; Rogers, Kai; Anantpadma, Manu; Singh, Brajesh K.; Sakurai, Yasuteru; Bair, Thomas; Miller-Hunt, Catherine; Sinn, Patrick; Davey, Robert A.; Monick, Martha M.; Maury, Wendy
Title: Interferon-? Inhibits Ebola Virus Infection
  • Document date: 2015_11_12
  • ID: 10bu7iwg_4
    Snippet: The ability of IFNs other than type I IFN to control EBOV infection has not been explored and several lines of reasoning suggest that type II IFN, interferon gamma (IFNγ), would inhibit EBOV infection of macrophages. Macrophages treated with IFNγ alone or in combination with tumor necrosis factor alpha (TNFα) are activated towards a M1 phenotype that is characteristically proinflammatory and antiviral, enhancing host defenses [14] [15] [16] . .....
    Document: The ability of IFNs other than type I IFN to control EBOV infection has not been explored and several lines of reasoning suggest that type II IFN, interferon gamma (IFNγ), would inhibit EBOV infection of macrophages. Macrophages treated with IFNγ alone or in combination with tumor necrosis factor alpha (TNFα) are activated towards a M1 phenotype that is characteristically proinflammatory and antiviral, enhancing host defenses [14] [15] [16] . As IFNγ directly stimulates the expression of a number of interferon-stimulated genes (ISGs) having antiviral activity [17, 18] , IFNγ treatment would be predicted to generate macrophages that are resistant to EBOV infection. Since it is thought that EBOV infection of macrophages is responsible for dysregulated cytokine production, reducing infection would likely reduce aberrant cytokine production concomitantly. Finally, as IFNγ potently activates T cell responses through enhancement of phagocytosis and antigen presentation [19] , such stimulation of antigen presentation would be predicted to enhance adaptive immune responses to in vivo infection.

    Search related documents:
    Co phrase search for related documents
    • adaptive immune response and antigen phagocytosis: 1
    • adaptive immune response and antigen presentation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immune response and antiviral activity: 1, 2, 3, 4, 5, 6, 7, 8
    • adaptive immune response and cell response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immune response and cytokine production: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • adaptive immune response and EBOV infection: 1, 2
    • adaptive immune response and ebov infection control: 1
    • adaptive immune response and IFNγ interferon gamma: 1
    • adaptive immune response and IFNγ treatment: 1, 2
    • antigen phagocytosis and cytokine production: 1, 2
    • antigen phagocytosis and EBOV infection: 1
    • antigen presentation and cell response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antigen presentation and cytokine production: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • antigen presentation and EBOV infection: 1, 2
    • antiviral activity and cell response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • antiviral activity and cytokine production: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antiviral activity and EBOV infection: 1, 2, 3, 4, 5
    • antiviral activity and ebov infection control: 1
    • antiviral activity and ebov infection control ifn: 1